An Open-label, Dose-finding, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of DNP002 in Patients With Advanced Solid Tumors
Latest Information Update: 10 Jul 2024
At a glance
- Drugs DNP 002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- 24 Jun 2024 New trial record